BioNxt Solutions, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA0909741062
CAD
0.64
-0.02 (-3.03%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BioNxt Solutions, Inc. stock-summary
stock-summary
BioNxt Solutions, Inc.
Pharmaceuticals & Biotechnology
Xphyto Therapeutics Corp. is a Canada-based cannabis company. The Company is engaged in developing a testing, manufacturing, and research business in Canada and a research, cultivation, import, manufacturing, and distribution business in Germany. The principal business of the Company is the business of medicinal cannabis including production, extraction, isolation, formulation, delivery, marketing and sales. The Company’s subsidiary, XPhyto Laboratories Inc, is focused on development of an analytical testing and extract manufacturing business. Its subsidiary, Vektor Pharma TF GmbH, is a German narcotics manufacturer, importer and researcher and focuses on designing, testing and manufacturing of thin film drug delivery systems, particularly transdermal patches and sub-lingual strips.
Company Coordinates stock-summary
Company Details
Suite 270 - 1820 Fir Street , VANCOUVER BC : V6J 3B1
stock-summary
Tel: 1 780 8186422
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 98 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.84

stock-summary
Return on Equity

70.37%

stock-summary
Price to Book

-11.60